The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Gregg Stone cast doubt on its reliability in trials, while David Cohen said QoL matters to patients and should be measured.

Merging interventional and AHFTC training programs would be a boon for patients and the HF subspecialty, experts argue.

Demystifying the AED, and training a generation of kids in their use, is key to prevent “catastrophic” sudden deaths in young ...

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

The complications portend a rise in the arrhythmia, and also in mortality, with an average time to event of 7 years.

Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

A minority of studies used the standard three-point MACE endpoint, and many tweaked their endpoints along the way.

The findings are disappointing, but questions around intervention timing, patient population, and others remain to be ...